menu

CME: Targeting the JAK/STAT Pathway in Immune-mediated Inflammatory Diseases: Current and Future Directions

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Targeting the JAK/STAT Pathway in Immune-mediated Inflammatory Diseases: Current and Future Directions

Targeting the JAK/STAT Pathway in Immune-mediated Inflammatory Diseases: Current and Future Directions
RestartResume
This activity will provide clinical data and expert opinions to aid in providing the best possible care to patients with RA and IBD.

Available credits: 1.00

Time to complete: 60 minutes

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Rheumatoid arthritis (RA) and inflammatory bowel disease (IBD) are chronic, systemic, autoimmune disorders characterized by inflammatory processes. There are numerous classes of therapies available to treat RA and IBD, and some patients achieve low disease activity or remission, yet a proportion of patients exhibits an inadequate response and/or discontinues therapy due to tolerability. As such, investigations into new targets and therapies, such as the janus kinase (JAK) inhibitors, continue. The introduction of JAK inhibitors further contributes to a growing armamentarium of therapies for these immune-mediated inflammatory diseases. Evolving strategies for employing the JAK inhibitors present a decision-making challenge to clinicians who treat these patients.

  • Provider(s)/Educational Partner(s)

  • Commercial Support

    Supported by an educational grant from Gilead Sciences, Inc.   

  • Intended Audience

    This activity is intended for gastroenterologists, rheumatologists and other clinicians interested in learning more about the JAK/STAT signaling pathway.

  • Educational Objectives

    Upon completion of this activity, participants will be able to:

    • Discuss the role of the JAK/STAT signaling pathway in the inflammation and disease progression of immune-mediated inflammatory diseases
    • Evaluate the use of JAK inhibitors in immune-mediated inflammatory diseases such as RA and IBD
    • Interpret clinical trial efficacy and safety data of JAK inhibitors under investigation across inflammatory diseases
    • Outline approaches to educating patients on the role of JAK inhibition, including efficacy and safety data
  • Accreditor Disclosure of Conflicts of Interest Policy

    The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME activity. 

    Faculty Info:

    Russell Cohen, MD(Moderator)
    Professor of Medicine
    Directory, Inflammatory Bowel Disease Center
    Co-Director, Advanced IBD Fellowship Program
    University of Chicago Medical Center
    Chicago, Illinois 

    William Rigby, MD (Faculty)
    Professor of Medicine, Microbiology and Immunology
    Division of Rheumatology
    Vice Chairman, Academic Affairs
    Department of Medicine
    Dartmouth Medical School
    Dartmouth-Hitchcock Medical Center
    Lebanon, New Hampshire 

    Joel Pekow, MD (Faculty)
    Assistant Professor of Medicine
    Section of Gastroenterology, Hepatology and Nutrition
    University of Chicago Medicine and Biological Sciences
    Chicago, Illinois

    Faculty Disclosures:

    The following financial relationships have been provided: 

    Russell Cohen, MD
    Speakers’ Bureau: AbbVie, Takeda Pharmaceuticals, Inc.
    Consultant/Advisory Board: AbbVie, Celgene Corporation, Entera Health, Inc., Hospira, Janssen, Pfizer, Inc., Sandoz Biopharmaceuticals, Takeda Pharmaceuticals, Inc., UCB S.A.
    Clinical Investigator: AstraZeneca, Celgene Corporation, Gilead Sciences, Inc., MedImmune, Mesoblast Ltd., Osiris Therapeutics, Inc., Pfizer Inc., Receptos, RedHill Biopharma, Sanofi-Aventis, USB S.A.

    William Rigby, MD
    Consulting Agreements: Bristol-Myers Squibb, Pfizer Inc., Roche

    Joel Pekow, MD
    Sources of Funding for Research: AbbVie, Takeda Pharmaceuticals, Inc.
    Consultant/Advisory Board: Janssen, Pfizer, Inc., Verastem Inc.

    Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: JAK inhibitors under investigation for RA and IBD. 

    Accreditor Disclosure:

    ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

  • Accreditation Statement(s)

    The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity

  • Disclosure of Unlabeled Use

    This CME activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

    Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: JAK inhibitors under investigation for RA and IBD.  

  • Disclaimer

    The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

    This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

  • Instructions

    This activity will take approximately 60 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 75% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

    Inquiries may be directed to ACHL at (877) 444-8435 x160

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments

You must be in to display playlists.

Get a Dose of ReachMD in Your Inbox
and Practice Smarter Medicine

Stay current with the best in medical education.